INM
InMed Pharmaceuticals Inc.
Key Financials
Net Income
$-8162133
↓ 6.3%
Gross Profit
$1.7M
↑ 55.0%
Operating Income
$-7947622
↑ 57.3%
Total Assets
$15.6M
↑ 31.8%
EPS (Diluted)
$-8.36
↓ 727.7%
Revenue
$4.9M
↑ 7.5%
Shareholders' Equity
$13.4M
↑ 45.9%
Total Liabilities
$2.1M
↓ 18.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| S-4 | 7/2/2026 | View on SEC |
| SCHEDULE 13D | 6/10/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 3 | 6/10/2026 | View on SEC |
| 8-K | 6/10/2026 | View on SEC |
| SCHEDULE 13G | 6/5/2026 | View on SEC |
| SCHEDULE 13G | 5/27/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 3 | 5/21/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INM |
| Company Name | InMed Pharmaceuticals Inc. |
| CIK | 1728328 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | A1 |
| Phone | (604) 669-7207 |